In addition, one study utilizing sera collected from CLL patients demonstrated patients were frequently deficient in C1q, C3, and C4 complement proteins and that their sera were more readily exhausted of complement activity following anti-CD20 mAb treatment, resulting in lowered CDC activity (119). Here, C3 is linked to B-cell chronic lymphocytic leukemia.